BPC-157

Overview

BPC-157 is a synthetic fifteen-residue peptide corresponding to a partial sequence of Body Protection Compound, a protein identified in human gastric juice. It is studied in research on tissue repair, angiogenesis and gastrointestinal protection, and is among the most widely discussed research peptides of the last decade.

It is also a compound where the gap between how confidently it is described in secondary sources and what the primary literature actually establishes is unusually wide. This page tries to be accurate about both.

Chemical identity

• Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
• CAS number: 137525-51-0
• Molecular formula: C₆₂H₉₈N₁₆O₂₂
• Molecular weight: 1419.5 g/mol
• Classification: Gastric pentadecapeptide, BPC partial sequence
• Length: 15 residues, all standard L-amino acids
• Appearance: White lyophilised powder

At 1,420 g/mol the molecule sits just past the point where a two-dimensional depiction remains readable at article width, so the sequence above is the more useful representation.

Two features of that sequence matter practically. Four of the fifteen residues are proline, which constrains the backbone into a relatively rigid conformation and contributes to protease resistance — part of why the parent compound survives in gastric juice, an environment designed to digest proteins. And the sequence contains no cysteine, no methionine and no aromatic residues at all: no tryptophan, tyrosine or phenylalanine. That absence has consequences for both handling and analysis, covered below.

Where it comes from

Body Protection Compound is a protein found in gastric juice, identified during research into why the stomach lining tolerates an environment that would destroy most tissue. BPC-157 is a fifteen-residue fragment of that larger protein, synthesised as a defined sequence.

It is described in the literature as a “stable gastric pentadecapeptide”, and the stability is the point: unlike most peptides, it is reported to remain intact in gastric acid rather than being degraded. That property is what made a fragment of a gastric protein interesting as a research compound in the first place.

Mechanism: what is proposed and what is established

This is where care is needed, because BPC-157 is frequently described as though its mechanism were settled. It is not.

No specific receptor for BPC-157 has been identified. The proposed mechanisms in the published literature are several and only partly overlapping:

• Angiogenic signalling. The most developed line, associating the peptide with VEGF receptor 2 activity and with formation of new blood vessels — a plausible common thread beneath repair findings across several tissue types.
• Nitric oxide pathway modulation. A substantial body of work relates the compound’s effects to NO signalling, including experiments using NO synthase inhibitors and donors to probe the dependency.
• Growth hormone receptor expression. Independent work in tendon fibroblasts reported increased growth hormone receptor expression following exposure, suggesting sensitisation to an existing signal rather than direct agonism.
• Focal adhesion and cell migration pathways. Reported effects on FAK–paxillin signalling, consistent with the cell migration that tissue repair requires.

What these have in common is that they describe correlates of the peptide’s presence rather than a defined molecular target it binds. A compound with wide-ranging reported effects and no identified receptor is an open scientific question, and worth treating as one.

Areas of research investigation

Gastrointestinal protection

The original and most extensive line, following directly from the compound’s origin. Work covers mucosal injury models and inflammatory conditions of the gut.

Tendon, ligament and muscle

The line that has attracted most outside attention, examining healing in connective tissue injury models. Some of the most useful work here is independent of the originating group.

This is also the context in which BPC-157 is most often combined with other compounds — typically TB-500, and sometimes GHK-Cu and KPV. The rationale for pairing with TB-500 is set out on that page: the two are studied for overlapping outcomes through non-overlapping mechanisms, which is a mechanistic argument rather than a demonstrated one.

Vascular and systemic effects

Studies examining angiogenesis directly, and a broader set looking at organ systems including liver, nervous tissue and vasculature.

The shape of the evidence

An honest account has to address who produced the literature, because it affects how much weight it carries.

A large proportion of published BPC-157 research originates from a single group led by Predrag Sikirić at the University of Zagreb, which has worked on the compound since the 1990s and accounts for a substantial share of the total output. Concentration of that kind is not evidence of error — a group that discovers a compound naturally publishes most of the early work on it — but it does mean that independent replication carries disproportionate weight, and that a body of literature can look larger than the number of independent confirmations behind it.

BPC-157 is better off here than some compounds. There is independent work, notably from groups in Taiwan examining tendon fibroblast responses, and that independence is part of why the tendon findings are among the more solid in the field. But the balance is worth knowing when reading a citation count.

The second point is that the research is overwhelmingly preclinical — rodent models and cell culture. Human data is minimal.

Regulatory status

BPC-157 is not an approved medicine in any major jurisdiction. Beyond that baseline, two points of regulatory context are worth being aware of when reading about this compound, as both have shaped its availability and how it is discussed:

• It appears on the World Anti-Doping Agency’s prohibited list, which is relevant to any research context involving competitive athletes.
• United States regulators have addressed its use in pharmacy compounding, placing it in a category identified with significant safety questions.

Neither affects its status as a research chemical, but both are part of an accurate picture and are easily verified against the current WADA list and FDA guidance.

Reported observations

Across the preclinical literature, BPC-157 is generally described as well tolerated in the models examined, with few adverse findings reported at the doses studied. That statement carries a caveat worth stating plainly: an absence of reported adverse findings in predominantly short-duration rodent studies from a concentrated set of authors is weaker evidence of safety than the same statement would be from a broad, independent, long-duration literature. The absence of signal and the absence of thorough looking are difficult to distinguish here.

Handling, reconstitution and storage

BPC-157 is among the more forgiving peptides in this catalogue, and its sequence explains why.

• No oxidation-prone residues. The sequence contains no methionine and no cysteine, removing the two most common chemical degradation routes for peptides.
• No photosensitive residues. With no tryptophan, light exposure is a far smaller concern than for compounds such as GHRP-6.
• Lyophilised storage: sealed and refrigerated is sufficient; freeze for long-term storage.
• Reconstitution: add diluent slowly down the vial wall, allow to dissolve undisturbed, do not shake. Mechanical denaturation remains a risk even for a stable sequence.
• After reconstitution: refrigerate and minimise freeze–thaw cycles.
• Concentration: our peptide reconstitution calculator converts vial quantity, diluent volume and syringe size into concentration per unit.

Purity and analytical verification

The same absence of aromatic residues that makes BPC-157 stable makes it harder to analyse, and this is a genuine and under-discussed point.

Peptide HPLC commonly uses ultraviolet detection at 280 nm, where tryptophan and tyrosine absorb strongly. BPC-157 contains neither — it has no aromatic residues at all — so it is effectively invisible at that wavelength. Analysis must instead use 214 nm, where the peptide bond itself absorbs.

That works, but it is less selective. At 214 nm almost everything absorbs, including solvents, buffer components and non-peptide contaminants, so the baseline is noisier and co-eluting impurities are harder to distinguish. A purity figure for this compound is therefore doing more difficult work than the same figure for a tryptophan-containing peptide.

The practical consequence: for BPC-157, ask what wavelength the HPLC purity was determined at, and give more weight to mass spectrometric confirmation than you might for a peptide with a strong chromophore.

We publish third-party certificates of analysis by batch.

References

• Sikirić P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011. PMID 21548867
• Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011. PMID 21030672
• Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 2014. PMID 25415472

Summary

BPC-157 is a synthetic pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, molecular formula C₆₂H₉₈N₁₆O₂₂, molecular weight 1,419.5 g/mol, corresponding to a partial sequence of a protein found in gastric juice. Four prolines and an absence of oxidation-prone residues make it unusually stable, both biologically and in storage. Research covers gastrointestinal protection, connective tissue repair and angiogenesis, with several proposed mechanisms and no identified receptor. The literature is extensive but concentrated in one originating group and almost entirely preclinical — a compound of genuine research interest where the confidence of secondary descriptions outruns what the primary work establishes.

For laboratory research use only. Not for human consumption. This material is not a drug, food, or cosmetic and may not be sold or used for any purpose other than in vitro or non-human laboratory research.